EULAR definition of difficult-to-treat rheumatoid arthritis

被引:304
|
作者
Nagy, Gyorgy [1 ,2 ]
Roodenrijs, Nadia M. T. [3 ]
Welsing, Paco M. J. [3 ]
Kedves, Melinda [4 ]
Hamar, Attila [5 ]
van der Goes, Marlies C. [3 ,6 ]
Kent, Alison [7 ]
Bakkers, Margot [8 ]
Blaas, Etienne [3 ]
Senolt, Ladislav [9 ,10 ]
Szekanecz, Zoltan [5 ]
Choy, Ernest [11 ]
Dougados, Maxime [12 ]
Jacobs, Johannes W. G. [3 ]
Geenen, Rinie [13 ]
Bijlsma, Hans W. J. [3 ]
Zink, Angela [14 ,15 ]
Aletaha, Daniel [16 ]
Schoneveld, Leonard [17 ]
van Riel, Piet [18 ]
Gutermann, Loriane [19 ]
Prior, Yeliz [20 ]
Nikiphorou, Elena [21 ]
Ferraccioli, Gianfranco [22 ]
Schett, Georg [23 ,24 ]
Hyrich, Kimme L. [25 ,26 ]
Mueller-Ladner, Ulf [27 ]
Buch, Maya H. [25 ,26 ,28 ]
McInnes, Iain B. [29 ]
van der Heijde, Desiree [30 ]
van Laar, Jacob M. [3 ]
机构
[1] Semmelweis Univ, Dept Rheumatol, Dept Internal Med 3, Budapest, Hungary
[2] Semmelweis Univ, Dept Genet Cell & Immunobiol, Budapest, Hungary
[3] Univ Utrecht, Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands
[4] Bacs Kiskun Cty Hosp, Dept Rheumatol, Kecskemet, Hungary
[5] Univ Debrecen, Fac Med, Dept Rheumatol, Debrecen, Hungary
[6] Meander Med Ctr, Dept Rheumatol, Amersfoort, Netherlands
[7] Salisbury Fdn Trust NHS Hosp, Salisbury, Wilts, England
[8] EULAR Standing Comm People Arthrit Rheumatism Eur, Zurich, Switzerland
[9] Charles Univ Prague, Fac Med 1, Dept Rheumatol, Prague, Czech Republic
[10] Inst Rheumatol, Prague, Czech Republic
[11] Cardiff Univ, CREATE Ctr, Sch Med, Sect Rheumatol,Div Infect & Immun, Cardiff, Wales
[12] Univ Paris, Hop Cochin, AP HP,Clin Epidemiol & Biostat, Dept Rheumatol,PRES Sorbonne Paris Cite,INSERM,U1, Paris, France
[13] Univ Utrecht, Dept Psychol, Utrecht, Netherlands
[14] Univ Med, Charite, Epidemiol Unit, German Rheumatism Res Ctr, Berlin, Germany
[15] Univ Med, Charite, Rheumatol, Berlin, Germany
[16] Med Univ Vienna, Div Rheumatol, Dept Internal Med 3, Vienna, Austria
[17] Bravis Hosp, Dept Rheumatol, Roosendaal, Netherlands
[18] Radboud Univ Nijmegen, Med Ctr, Dept Rheumat Dis, Nijmegen, Netherlands
[19] Paris Descartes Univ, Hop Cochin, AP HP, Dept Pharm, Paris, France
[20] Univ Salford, Ctr Hlth Sci Res, Sch Hlth & Soc, Salford, Lancs, England
[21] Kings Coll London, Ctr Rheumat Dis, London, England
[22] Univ Cattolica Sacro Cuore, Sch Med, Rome, Italy
[23] Friedrich Alexander Univ Erlangen Nuremberg, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany
[24] Univ Klinikum Erlangen, Erlangen, Germany
[25] Cent Manchester NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Musculoskeletal Biomed Res Unit, Manchester, Lancs, England
[26] Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Ctr Musculoskeletal Res, Manchester, Lancs, England
[27] Justus Liebig Univ Giessen, Kerckhoff Clin Bad Nauhe, Dept Rheumatol & Clin Immunol, Bad Nauheim, Germany
[28] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[29] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland
[30] Leiden Univ, Dept Rheumatol, Med Ctr, Leiden, Netherlands
关键词
RECOMMENDATIONS;
D O I
10.1136/annrheumdis-2020-217344
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking. Objective The Task Force in charge of the "Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis" aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step. Methods The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting). Results The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA: (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of >= 2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following: at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient. Conclusions The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.
引用
收藏
页码:31 / 35
页数:5
相关论文
共 50 条
  • [21] Characterizing molecular targets in difficult-to-treat rheumatoid arthritis
    Smith, Melanie H.
    Bai, Zilong
    Lakhanpal, Amit
    Ramirez, Daniel
    Dicarlo, Edward
    Donlin, Laura
    Orange, Dana
    Goodman, Susan M.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2025, 70
  • [22] The potential role of fatigue in difficult-to-treat rheumatoid arthritis
    Leon, Leticia
    Freites-Nunez, Dalifer
    Madrid, Alfredo
    Rodriguez-Mariblanca, Maria
    Fernandez-Gutierrez, Benjamin
    Abasolo, Lydia
    BMC RHEUMATOLOGY, 2024, 8 (01)
  • [23] Difficult-to-treat psoriatic arthritis: moving out of the rheumatoid arthritis shadow
    Siebert, Stefan
    Marzo-Ortega, Helena
    NATURE REVIEWS RHEUMATOLOGY, 2024, 20 (03) : 135 - 136
  • [24] Difficult-to-treat psoriatic arthritis: moving out of the rheumatoid arthritis shadow
    Stefan Siebert
    Helena Marzo-Ortega
    Nature Reviews Rheumatology, 2024, 20 : 135 - 136
  • [25] A paradigm of difficult-to-treat rheumatoid arthritis: subtypes and early identification
    Novella-Navarro, M.
    Ruiz-Esquide, V.
    Torres-Ortiz, G.
    Chacur, C. A.
    Tornero, C.
    Fernandez-Fernandez, E.
    Monjo, I.
    Sanmarti, R.
    Plasencia-Rodriguez, C.
    Balsa, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (05) : 1114 - 1119
  • [26] Characteristics of Difficult-to-Treat Rheumatoid Arthritis: Results of an International Survey
    Roodenrijs, Nadia M. T.
    de Hair, Maria J. H.
    van der Goes, Marlies C.
    Jacobs, Johannes W. G.
    Welsing, Paco M. J.
    van der Heijde, Desiree
    Aletaha, Daniel
    Dougados, Maxime
    Hyrich, Kimme L.
    McInnes, Iain B.
    Mueller-Ladner, Ulf
    Senolt, Ladislav
    Szekanecz, Zoltan
    van Laar, Jacob
    Nagy, Gyorgy
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [27] A difficult-to-treat pleuropulmonary histoplasmosis in a patient with rheumatoid arthritis in Taiwan
    Chu, Wen -Kai
    Wu, Un-In
    Lee, Tai-Fen
    Cheng, Aristine
    Chen, Kai -Hsiang
    Lin, Kuan-Yin
    Chen, Yee-Chun
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2023, 56 (01) : 192 - 196
  • [28] Atypical Baker's cysts in difficult-to-treat rheumatoid arthritis
    Zoshima, Takeshi
    Hirayama, Sun
    Kawano, Mitsuhiro
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (11) : 2328 - 2329
  • [29] Non-pharmacological treatment in difficult-to-treat rheumatoid arthritis
    Majnik, Judit
    Csaszar-Nagy, Noemi
    Bocskei, Georgina
    Bender, Tamas
    Nagy, Gyorgy
    FRONTIERS IN MEDICINE, 2022, 9
  • [30] Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease
    Roodenrijs, Nadia M. T.
    van der Goes, Marlies C.
    Welsing, Paco M. J.
    Tekstra, Janneke
    Lafeber, Floris P. J. G.
    Jacobs, Johannes W. G.
    van Laar, Jacob M.
    RHEUMATOLOGY, 2021, 60 (08) : 3778 - 3788